PTC Therapeutics (PTCT) Stock: Here’s What You Need To Know

PTC Therapeutics (NASDAQ:PTCT) On Monday, PTC Therapeutics fell by 40% to $7.97 per share after the company had announced that the FDA refused its appeal for a refuse-to-file letter. PTC Therapeutics has not been able to get the FDA to back its Duchenne Muscular Dystrophy — DMD — drug. What happened was that PTC had … Read more

Sarepta Therapeutics (SRPT) Stock: Here’s What You Need To Know

Sarepta Therapeutics (NASDAQ:SRPT) On Monday, Sarepta’s stock closed the day up 73.85% after the company announced that the FDA had given its drug Eteplirsen FDA approval. More specifically, the company filed for accelerated approval. In other words, drugs can be approved after only completing a phase 2 study if the results show that a surrogate … Read more

Biotech Stock News (SRPT) (BMRN) (ACAD)

Sarepta Therapeutics (NASDAQ:SRPT) On Monday April 25, 2016 Sarepta Therapeutics had an FDA advisory panel shoot down its drug Eteplirsen, used to treat patients with Duchenne Muscular Dystrophy — DMD. The panel voted against Eteplirsen on all questions. Even the last question which asked if Eteplirsen should be approved for DMD patients was also voted … Read more

Biotech Stock News (RXII) (SRPT)

Rxi Pharmaceuticals (NASDAQ:RXII) On Tuesday April 19, 2016 Rxi Pharmaceuticals announced that it would present pre-clinical data at a medical conference, known as 2016 ARVO Conference. ARVO stands for Association for Research in Vision and Ophthalmology. The pre-clinical data to be presented will be the company’s drug in corneal scarring. In order to prevent injury … Read more

Biotech Stock News (SRPT) (JUNO) (CELG) (AGTC) (VRTX)

Sarepta Therapeutics (NASDAQ:SRPT) On Monday June 29, 2015 Sarepta had announced that it had completed¬†its rolling submission of its New Drug Application — NDA — to the FDA. A rolling submission is an FDA policy whereby biotech companies can submit their marketing approval application in small parts on a rolling basis instead of doing it … Read more

Biotech Stock News (HZNP)(HPTX)(XON)(SRPT)(MDVN)(ALPMY)(AZN)

Horizon Pharma (NASDAQ:HZNP) Shares of Horizon Pharma ended the day up 18% on March 30, 2015 after the company announced that it would acquire Hyperion Therapeutics (NASDAQ:HPTX) for $955.7 million dollars. Although one thing to note is that this deal for $955.7 million dollars will be a mix of a cash and debt deal. The … Read more